Original Article
Author Details :
Volume : 3, Issue : 4, Year : 2016
Article Page : 611-615
Abstract
Objective: To study the effect of low dose intrathecal dexmedetomidine as adjuvant to hyperbaric Bupivacaine in relation to onset & duration of sensory & motor block.
Material and Methods: In the present double blinded prospective, randomized controlled trial study, we have aimed to compare the two groups of ASA –grade I patients divided in two groups i.e., group B - Bupivacaine 2.5ml (12.5 mg) alone (control group) and group BD - Bupivacaine 2.5 ml (12.5 mg) combined with Dexmedetomidine 5 ?g undergoing lower abdominal and lower limb surgeries to evaluate whether there is any clinching evidence of augmentation of motor and sensory block by addition of low dose dexmedetomidine (5?g).
Results: Among both the groups, mean time to achieve onset of sensory & motor blockade was found to be not statistically significant (P>0.05). The duration of sensory block observed in group BD was 143.6±12.74 in contrast to group B 107±9.74. The difference in mean duration of analgesia between group B vs. BD, is statistically significant (P<0.001).The duration of motor blockade in group B found was 174.2±11.26 in relation of group BD 276.4±13.96which is statistically significant (P<0.001).
Conclusions: It was concluded from the present study that addition of low dose dexmedetomidineto hyperbaric bupivacaine for subarachnoid block definitely prolongs the duration of sensory and motor blockade.
Keywords: Dexmedetomidine, Hyperbaric Bupivacaine, Sub arachnoid block
How to cite : Gupta S, Gupta A, Sarkar B P, A prospective double blinded study on effect of intrathecal dexmedetomidine as adjuvant to hyperbaric bupivacaine on onset and duration of subarachnoid blockade. Indian J Clin Anaesth 2016;3(4):611-615
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.